Key facts
- This page summarizes Ms. Sarah Li's Form 4 filing for InMed Pharmaceuticals Inc. (INM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 19 Dec 2022, 16:03.
Ms. Sarah Li - 16 Dec 2022 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)
- Reporting relationship
- VP Accounting & Controller
- Issuer ticker
- INM
- Reported as of
- 16 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Dec 2022, 16:03:37 UTC
- Prior SEC filing
- 29 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric A Adams, attorney-in-fact for Ms. Sarah Li
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Ms. Sarah Li filed Form 4 for InMed Pharmaceuticals Inc. (INM) on 19 Dec 2022.
Change
- Previous filing in this sequence was filed on 29 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INM
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +3,600
- Change %
- +896%
- Price
- $0.000000
- Shares after
- 4,002
- Date
- 16 Dec 2022
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
- 3,600
- Exercise price
- $1.78
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.